Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6283)
All Articles published online
|
Publishing Process of This Article
|
Jun 6, 2021 (publication date) through Feb 21, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bian LF, Zheng C, Shi XL. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report. World J Clin Cases 2021; 9(16): 4110-4115 [PMID: 34141773 DOI: 10.12998/wjcc.v9.i16.4110] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i16/4110.htm |
| Number | Citing Articles |
| 1 |
Benjamin C. Park, Cosby A. Stone, Anna K. Dewan, Douglas B. Johnson. Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. Immunology and Allergy Clinics of North America 2022; 42(2): 285 doi: 10.1016/j.iac.2021.12.006
|
| 2 |
Ji Hyun Oh, Kwang Il Seo, Hee-Kyoo Kim, Gil-Soon Choi. Successful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review. Asia Pacific Allergy 2024; 14(3): 139 doi: 10.5415/apallergy.0000000000000138
|
| 3 |
Atezolizumab/camrelizumab/lenvatinib. Reactions Weekly 2021; 1876(1): 63 doi: 10.1007/s40278-021-03312-6
|
| 4 |
Margarita Giraldo-Tugores, Carlos Fernández-Lozano, Alejandra Carrón-Herrero, Pablo Gajate, Javier Martinez-Botas, Cristina Pueyo-López, Emilio Solano-Solares, María Pilar Berges-Gimeno. Successful rapid desensitization to atezolizumab in delayed hypersensitivity confirmed with lymphocyte transformation test. The Journal of Allergy and Clinical Immunology: In Practice 2022; 10(6): 1649 doi: 10.1016/j.jaip.2021.12.041
|
| 5 |
A. Barroso, F. Estevinho, V. Hespanhol, E. Teixeira, J. Ramalho-Carvalho, A. Araújo. Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open 2024; 9(3): 102922 doi: 10.1016/j.esmoop.2024.102922
|
| 6 |
Guolong Zhang, Huiwen Weng, Yinghong Li, Pingdong Li, Yucui Gong, Jieya Chen, Lin Wei, Linghui Zeng, Yingchun Zeng, Andy SK. Cheng. Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy. Asia-Pacific Journal of Oncology Nursing 2022; 9(8): 100103 doi: 10.1016/j.apjon.2022.100103
|
| 7 |
Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim. Complications of immunotherapy in advanced hepatocellular carcinoma. Journal of Liver Cancer 2024; 24(1): 9 doi: 10.17998/jlc.2023.11.21
|
| 8 |
Seung Hyuk Lee, Hyeon Jong Kim, Hyun Jin Bang, Su Ji Park, Ji Eun Yu, Seung Woo Jeong, Woo Kyun Bae. Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1273043
|